Janssen announced FDA approval of CABENUVA, the first long-acting HIV treatment regimen
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenメs rilpivirine and ViiV…
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenメs rilpivirine and ViiV…
On Jan. 12, 2021, UC Berkeley HIV researchers announced that they had determined the atomic structure of a…
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
On Nov. 30, 2020, The National Institute of Allergy and Infectious Diseases (NIAID) announced the clinical investigators and…
On Nov. 23, 2020, Viatris announced tentative approval from the FDA for a New Drug Application for pediatric…
On Nov. 30, 2020, Hologic announced that the FDA had approved a diagnostic claim for its HIV-1 (human…
On Nov. 19, 2020, University of Oxford researchers announced that research into the HIV-1 virus had shed light…
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
On Nov. 13, 2020, Albert Einstein College of Medicine announced that it had received a five-year, $4.9 million…
On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form…
On Oct. 22, 2020, the World Health Organizationメs Global TB Programme welcomed the results from a landmark study…
On Oct. 6, 2020, Hologic announced that two studies in the Journal of Clinical Microbiology demonstrated the utility…
On Sept. 18, 2020, Uconn researchers, in a paper published in Nature Communications, validated the clinical feasibility of…
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
On Sept. 2, 2020, UT Southwestern (UTSW) announced that it had performed the first HIV-positive-to-HIV-positive organ transplant in…
On Sept. 1, 2020, Roche announced FDA approval for the cobasᆴ HIV-1/HIV-2 Qualitative Test for use on the…
On Aug. 31, 2020, AstraZeneca announced that the COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial…
On Aug. 11, 2020, Gilead Sciences announced that the China National Medical Products Administration (NMPA) had approved a…
On Jul. 31, 2020, the Centers for Disease Control and Prevention (CDC) awarded $109 million to state and…
On Jul. 23, 2020, kidney transplantation from deceased donors with HIV to people living with both HIV and…
On Jul. 8, 2020, Gilead Sciences announced data evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP…
On Jul. 7, 2020, a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug…
On Jul. 6, 2020, Merck announced a new analyses from the Phase 2b trial evaluating the safety and…
On Jul. 2, 2020, the U.S. Food and Drug Administration (FDA) approved Rukobia (fostemsavir), a new type of…
On Jul. 2, 2020, ViiV Healthcare, a GSK company, with Pfizer and Shionogi Limited, announced the FDA had…
On Jun. 12, 2020, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay (dolutegravir) tablets and…
On Jun. 12, 2020, ViiV Healthcare, a GSK company, with Pfizer and Shionogi Limited, announced the FDA had…
On Jun. 11, 2020, researchers have found that astrocytes, a type of brain cell can harbor HIV and…
On Jun. 8, 2020, Evotec announced that its Seattle-based subsidiary Just – Evotec Biologics had entered into an…
On May 26, 2020, the NIH announced a new study that provides an alternative treatment regimen that is…